Randomized Trial Comparing Colesevelam vs. Ezetimibe
Status:
Completed
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
A 24-week, randomized, open-label study investigating the efficacy, safety and tolerability
of colesevelam 3.75 g daily compared to ezetimibe 10 mg daily, as an add-on to baseline
statin therapy in patients with type 2 diabetes mellitus (T2DM) who are not at target for
glycated hemoglobin (HbA1c) (> 7.0%) and low-density lipoprotein (LDL) cholesterol (> 2.0
mmol/L).
Phase:
Phase 4
Details
Lead Sponsor:
LMC Diabetes & Endocrinology Ltd.
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.